In conclusion, unusual clinical or laboratory findings in patients with CLL, even in early stages, should prompt the diagnosis of a SM. Considering their aggressive clinical course and their association with worse survival, a strategy of more frequent cancer screening, such as biannual PSA tests, may allow for earlier identification of SMs. Here, KLK3 is linked to systemic mastocytosis.